Since the patent for imatinib has expired, the role of generic imatinib (GI) in the management
of Philadelphia chromosome–positive (Ph+) leukemia in pediatric patients has had ongoing …

Background: Imatinib is the gold standard in the treatment of chronic myeloid leukemia
(CML) patients. Resistance to imatinib is interfering with patients' responses and their …

Introduction Generics of imatinib mesylate, the first tyrosine kinase inhibitor targeting the
BCR-ABL1 fusion protein, have recently been approved in many countries as the alternative …

目的评估**慢性髓性白血病(CML) 慢性期(CP) 患者报告的酪氨酸激酶抑制剂(TKI)
相关不良反应及其对日常生活的影响. 方法2014 年5 月至11 月在全国范围内向**在接受TKI …

The aim of this study is survey of effects of Imatinib with dose 400 mg per day after 6 months
in the patients with CML chronic phase. Between of 2010-2014, fifty four patients with high …

Sixty patients with Chronic Myeloid Leukemia (CML) who were on oral imatinib were
included in this study. The study aimed to evaluate patients characteristic, tolerability and …

Imatinib mesylate, a selective BCR-ABL tyrosine kinase inhibitor, has been well established
as the standard of care for chronic myeloid leukaemia patients. In this study, we compared …

Background: Chronic myeloid leukemia (CML), is the first malignancy that related to the
chromosomal abnormality and include 15-20% of all adulthood leukemia. AIMS This study …

Objective: To explore the impact of patient reported outcome of tyrosine kinase inhibitor (TKI)
related side effects on daily life in Chinese patients with chronic myeloid leukemia (CML) in …

The beginning of the twenty-first century saw a breakthrough in haematology, oncology and
general medicine driven by the introduction of imatinib (Glivec) to the treatment of chronic …